Exelixis, Inc.

Exelixis Patent Company LLC

X-ceptor Therapeutics, Inc.

Novartis Ag

Irm LLC

Lion Bioscience Ag

Brenton Todd Flatt

Richard Martin

Tie-Lin Wang

Raju Mohan

Xiao-Hui Gu

Brett Bradley Busch

Michael Charles Nyman

Edwin J Schweiger

Jeffrey Dean Kahl

Jason H Wu

Venkataiah Bollu

Ronald Griffith

William C Stevens, Jr

Yinong Xie

Brett Murphy

Michael M Morrissey

Valentina Molteni

Yong Wang

Timothy Patrick Forsyth

Lynne Canne Bannen

Jon Christopher Loren

Larry Wayne Mann

Jeff Z Chen

Morrison B Mac

Jeffrey M Smith

Grace Mann

Benjamin Pratt

Yi Fan

Jackaline Dalgard Julien

Brant Clayton Boren

Lisa Esther Dalrymple

Nadia Haq

Shao Po Lu

Sarah Hudson

William C Stevens

Pamela Ann Albaugh

Ping Huang

Gregory B Chopiuk

Shao-Po Lu

Jackline Eve Dalgard

Alan Katritzky

Behrouz Bruce Forood

Jeff Chen

Christophe Chassaing

Tie Lin Wang

Xiao Hui Gu

William Stevens

Jeffery Dean Kahl

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.  

Compounds and compositions as TRK inhibitors

Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.

Imidazole based LXR modulators

TGR5 agonists of structural formula VIII(Q), wherein X, R, R, and Rare defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases. 

TGR5 agonists

The present invention comprises TGR5 agonists of structural formula I, wherein X, R, R, and Rare defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprises composition comprising the compounds, N-oxides, and/or pharmaceutically acceptable salts thereof. The invention also comprises use of the compounds and compositions for treating diseases in which TGR5 is a mediator or is implicated. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases in which TGR5 is a mediator or is implicated.

Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity

Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Quinazolinone modulators of nuclear receptors

Compounds of the invention, such as compounds of Formulae Ia, Ib, Ic, or Id and pharmaceutically acceptable salts, isomers, and prodrugs thereof, which are useful as modulators of the activity of liver X receptors, where R1, R2, R21, R3, and G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

Modulators of LXR

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TRK kinase activity.

Compounds of the invention, such as compounds of Formulae IIa, IIb, IIc or IId, and pharmaceutically acceptable salts, isomers, and prodrugs thereof, are useful as modulators of the activity of liver X receptors, where R, R, R, Rand G are defined herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed. 

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Azepinoindole derivatives as pharmaceutical agents

Compounds, compositions and methods are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder related to the activity of the receptors.

Azepine derivatives as pharmaceutical agents

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Pyrrole derivatives as pharmaceutical agents

A compound according to Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, Land X are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

11 &#x3b2;-HSD1 modulators

Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of the disease or disorder directly or indirectly related to the activity of the receptors.

Heterocyclic compounds as pharmaceutical agents

Growing community of inventors

Poway, CA, United States of America

Brenton Todd Flatt